Charles River Laboratories | CRL - Trade Debtors


Charles River Laboratories reported $700.25M in Trade Debtors for its fiscal quarter ending in March of 2026.





Trade Debtors Change Date
Agilent USD 1.5B 23M Mar/2026
Align Technology USD 1.13B 23.36M Mar/2026
Bio-Rad Laboratories USD 460.6M 4.1M Dec/2025
Bruker USD 542.7M 2.2M Mar/2026
Cardinal Health USD 13.65B 14M Mar/2026
Charles River Laboratories USD 700.25M 727.92M Mar/2026
Cigna USD 26.61B 6.26B Mar/2026
Concord Medical Services Hldg CNY 57.36M 40.75M Jun/2025
CVS Health USD 40.99B 1.21B Mar/2026
Danaher USD 4.76B 845M Mar/2026
Dentsply International USD 622M 66M Mar/2026
Elevance Health USD 22.79B 1.25B Mar/2026
Humana USD 5.22B 1.95B Mar/2026
Illumina USD 738M 116M Mar/2026
Incyte USD 1.05B 27.09M Mar/2026
Intrexon USD 1.02M 559K Jun/2024
IQVIA Holdings USD 3.38B 52M Mar/2026
Laboratory Of America USD 2.45B 189.8M Mar/2026
Lakefront Biotherapeutics EUR 54.03M 145.72M Mar/2026
Lonza CHF 1.78B 55M Dec/2025
McKesson USD 27.99B 228M Mar/2026
Merck EUR 4.81B 373M Mar/2026
Mettler Toledo International USD 708.21M 70.04M Mar/2026
Novartis USD 9.6B 2.69B Mar/2026
Pfizer USD 16.17B 332M Mar/2026
Quest Diagnostics USD 1.59B 179M Mar/2026
Revvity USD 691.38M 53.29M Mar/2026
Thermo Fisher Scientific USD 9.2B 304M Mar/2026
United Therapeutics USD 312M 38.2M Mar/2026
UnitedHealth USD 26.59B 3.57B Mar/2026
Veradigm USD 175.72M 58.76M Dec/2022
Waters USD 1.76B 930.16M Mar/2026
West Pharmaceutical Services USD 685.6M 111.2M Mar/2026